{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:22:19Z","timestamp":1792092139097,"version":"4.4.0"},"reference-count":89,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Dendritic cells (DCs) are central to cancer immunity, orchestrating both innate and adaptive immune responses. In melanoma and other solid tumors, however, their function is often impaired within the tumor microenvironment (TME), leading to weakened antitumor immunity and diminished responses to immune checkpoint inhibitors (ICIs) and adoptive tumor-infiltrating lymphocyte (TIL) therapy. Among the various cell-based immunotherapy approaches, DC therapy\u2014particularly using blood-derived conventional DCs (cDCs)\u2014holds considerable promise. Compared with traditional monocyte-derived DCs (moDCs), cDCs exhibit superior antigen processing and cross-presentation capacities. The therapeutic application of cDCs was initially pioneered in vaccine strategies involving ex vivo antigen loading and maturation, followed by administration to lymph nodes. More recently, intratumoral (IT) cDC immunotherapy has emerged as a strategy to reinvigorate the cancer-immunity cycle by engaging the full repertoire of tumor-associated antigens while limiting systemic toxicity. This review discusses the underlying biological mechanisms and summarizes the clinical outcomes of IT DC therapy in cancer. Notably, combination approaches incorporating IT cDCs with ICIs, oncolytic viruses, synthetic adjuvants, radiation, or cryotherapy are emerging as promising strategies to overcome both primary and acquired resistance to ICI monotherapy. Collectively, these findings highlight the potential of integrating IT cDC therapy with complementary immunotherapies in next-generation, cross-tumor treatment strategies.<\/jats:p>","DOI":"10.3390\/vaccines14050402","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:47:28Z","timestamp":1777546048000},"page":"402","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reinvigorating the Cancer-Immunity Cycle by Intratumoral Administration of Conventional Dendritic Cells in Melanoma and Other Solid Tumors: A Narrative Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2516-8390","authenticated-orcid":false,"given":"Manon","family":"Vounckx","sequence":"first","affiliation":[{"name":"Laboratory of Medical and Molecular Oncology (LMMO), Department of Medical Oncology, UZ Brussel, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium"},{"name":"Medical and Molecular Oncology, Translational Oncology Research Center (TORC), Brussels Health Campus, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2168-0781","authenticated-orcid":false,"given":"Iris","family":"Dirven","sequence":"additional","affiliation":[{"name":"Laboratory of Medical and Molecular Oncology (LMMO), Department of Medical Oncology, UZ Brussel, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium"},{"name":"Medical and Molecular Oncology, Translational Oncology Research Center (TORC), Brussels Health Campus, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7096-476X","authenticated-orcid":false,"given":"Cleo","family":"Bertels","sequence":"additional","affiliation":[{"name":"Laboratory of Medical and Molecular Oncology (LMMO), Department of Medical Oncology, UZ Brussel, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium"},{"name":"Medical and Molecular Oncology, Translational Oncology Research Center (TORC), Brussels Health Campus, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-5380","authenticated-orcid":false,"given":"Julia Katharina","family":"Schwarze","sequence":"additional","affiliation":[{"name":"Laboratory of Medical and Molecular Oncology (LMMO), Department of Medical Oncology, UZ Brussel, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0163-9482","authenticated-orcid":false,"given":"Xenia","family":"Geeraerts","sequence":"additional","affiliation":[{"name":"Laboratory of Medical and Molecular Oncology (LMMO), Department of Medical Oncology, UZ Brussel, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium"},{"name":"Medical and Molecular Oncology, Translational Oncology Research Center (TORC), Brussels Health Campus, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1255-8071","authenticated-orcid":false,"given":"Sandra","family":"Tuyaerts","sequence":"additional","affiliation":[{"name":"Laboratory of Medical and Molecular Oncology (LMMO), Department of Medical Oncology, UZ Brussel, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium"},{"name":"Medical and Molecular Oncology, Translational Oncology Research Center (TORC), Brussels Health Campus, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Boisson","sequence":"additional","affiliation":[{"name":"Molecular Immunology Unit (MIU), Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Willard-Gallo","sequence":"additional","affiliation":[{"name":"Molecular Immunology Unit (MIU), Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-5903","authenticated-orcid":false,"given":"Bart","family":"Neyns","sequence":"additional","affiliation":[{"name":"Laboratory of Medical and Molecular Oncology (LMMO), Department of Medical Oncology, UZ Brussel, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium"},{"name":"Medical and Molecular Oncology, Translational Oncology Research Center (TORC), Brussels Health Campus, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/10600280221131396","article-title":"Nivolumab\/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma","volume":"57","author":"Phillips","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Su, J., Fu, Y., Cui, Z., Abidin, Z., Yuan, J., Zhang, X., Li, R., and Zhao, C. (2023). Relatlimab: A novel drug targeting immune checkpoint LAG-3 in melanoma therapy. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1349081"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e005923","DOI":"10.1136\/jitc-2022-005923","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies","volume":"11","author":"Atkins","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kim, S.K., and Cho, S.W. (2022). The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.868695"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1111\/cas.15497","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"113","author":"Nagasaki","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/j.jmb.2018.05.030","article-title":"Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer","volume":"430","author":"Borcherding","year":"2018","journal-title":"J. Mol. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e006555","DOI":"10.1136\/jitc-2022-006555","article-title":"Addressing resistance to PD-1\/PD-(L)1 pathway inhibition: Considerations for combinatorial clinical trial designs","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/978-1-0716-3135-5_31","article-title":"In Vitro Generation of Human Tolerogenic Monocyte-Derived Dendritic Cells","volume":"2654","author":"Hilkens","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1738814","DOI":"10.1080\/2162402X.2020.1738814","article-title":"Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination","volume":"9","author":"Bloemendal","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00262-015-1688-2","article-title":"Engineering monocyte-derived dendritic cells to secrete interferon-alpha enhances their ability to promote adaptive and innate anti-tumor immune effector functions","volume":"64","author":"Willemen","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","article-title":"Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma","volume":"34","author":"Wilgenhof","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1158\/1078-0432.CCR-09-1254","article-title":"Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma","volume":"15","author":"Ribas","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1201625","DOI":"10.1080\/2162402X.2016.1201625","article-title":"Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination","volume":"5","author":"Boudewijns","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: The first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s00262-020-02618-4","article-title":"A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III\/IV melanoma patients who are disease-free following the resection of macrometastases","volume":"69","author":"Jansen","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","article-title":"Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma","volume":"75","author":"Zimmer","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00262-019-02466-x","article-title":"Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: A prospective, randomized phase 2 trial","volume":"69","author":"Boudewijns","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-0716-2938-3_2","article-title":"Phenotypes and Functions of Human Dendritic Cell Subsets in the Tumor Microenvironment","volume":"2618","author":"Sakref","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","article-title":"Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors","volume":"42","author":"Chiu","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ccell.2014.11.010","article-title":"Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e1086862","DOI":"10.1080\/2162402X.2015.1086862","article-title":"Tumor-intrinsic oncogene pathways mediating immune avoidance","volume":"5","author":"Spranger","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s43556-025-00300-8","article-title":"Dendritic cells: Understanding ontogeny, subsets, functions, and their clinical applications","volume":"6","author":"Li","year":"2025","journal-title":"Mol. Biomed."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Galan","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e1192739","DOI":"10.1080\/2162402X.2016.1192739","article-title":"Human CD1c+ DCs are critical cellular mediators of immune responses induced by immunogenic cell death","volume":"5","author":"Wortel","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1182\/blood-2013-04-495424","article-title":"Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses","volume":"122","author":"Nizzoli","year":"2013","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41590-022-01324-w","article-title":"Mechanisms of CD40-dependent cDC1 licensing beyond costimulation","volume":"23","author":"Wu","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Saito, Y., Komori, S., Kotani, T., Murata, Y., and Matozaki, T. (2022). The Role of Type-2 Conventional Dendritic Cells in the Regulation of Tumor Immunity. Cancers, 14.","DOI":"10.3390\/cancers14081976"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e011519","DOI":"10.1136\/jitc-2025-011519","article-title":"Role of cDC2 in priming CD8+ T cells in cancer","volume":"13","author":"Hamouda","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Salvi","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"ltaf021","DOI":"10.1093\/immadv\/ltaf021","article-title":"Comparing DC subsets in solid tumors: What about DC3s?","volume":"5","author":"Pachocki","year":"2025","journal-title":"Immunother. Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1189\/jlb.1104664","article-title":"Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity","volume":"78","author":"Tan","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nri1592","article-title":"Dendritic cells as therapeutic vaccines against cancer","volume":"5","author":"Banchereau","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1440-1711.2005.01371.x","article-title":"Dendritic cell dysfunction in cancer: A mechanism for immunosuppression","volume":"83","author":"Maxwell","year":"2005","journal-title":"Immunol. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0092-8674(00)80059-8","article-title":"CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs","volume":"99","author":"Forster","year":"1999","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/imt.09.43","article-title":"Directing dendritic cell immunotherapy towards successful cancer treatment","volume":"2","author":"Sabado","year":"2010","journal-title":"Immunotherapy"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0092-8674(01)00449-4","article-title":"Dendritic cells: Specialized and regulated antigen processing machines","volume":"106","author":"Mellman","year":"2001","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"XII74","DOI":"10.1093\/annonc\/mdx727","article-title":"Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy","volume":"28","author":"Teijeira","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","article-title":"PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1546068","DOI":"10.1080\/2162402X.2018.1546068","article-title":"Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy","volume":"8","author":"Liu","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","article-title":"Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy","volume":"50","author":"Chow","year":"2019","journal-title":"Immunity"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.immuni.2022.07.021","article-title":"Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-\u03b3 and IL-12","volume":"55","author":"Garris","year":"2022","journal-title":"Immunity"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"eabg2752","DOI":"10.1126\/science.abg2752","article-title":"CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses","volume":"379","author":"He","year":"2023","journal-title":"Science"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","article-title":"PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer","volume":"1","author":"Oh","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.immuni.2021.04.019","article-title":"The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake","volume":"54","author":"Pulido","year":"2021","journal-title":"Immunity"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","article-title":"TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer","volume":"33","author":"Pulido","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s43018-022-00329-6","article-title":"Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting","volume":"3","author":"Salomon","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e25771","DOI":"10.4161\/onci.25771","article-title":"Trial watch: Dendritic cell-based interventions for cancer therapy","volume":"2","author":"Vacchelli","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40425-019-0580-6","article-title":"The clinical application of cancer immunotherapy based on naturally circulating dendritic cells","volume":"7","author":"Bol","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1158\/1078-0432.CCR-15-2205","article-title":"Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells","volume":"22","author":"Schreibelt","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41467-024-45358-0","article-title":"Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: The MIND-DC randomized phase III trial","volume":"15","author":"Bol","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2015113","DOI":"10.1080\/2162402X.2021.2015113","article-title":"Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients","volume":"11","author":"Bloemendal","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s11912-023-01422-4","article-title":"Intratumoral Immunotherapy: Is It Ready for Prime Time?","volume":"25","author":"Ghosn","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/annonc\/mdy423","article-title":"Starting the fight in the tumor: Expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","volume":"29","author":"Marabelle","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"XII33","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: Using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1634\/theoncologist.2019-0438","article-title":"Intratumoral Immunotherapy-Update 2019","volume":"25","author":"Hamid","year":"2020","journal-title":"Oncologist"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1890512","DOI":"10.1080\/21645515.2021.1890512","article-title":"Intratumoral therapies and in-situ vaccination for melanoma","volume":"18","author":"Huppert","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-12-0781","article-title":"Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects","volume":"19","author":"Fransen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","article-title":"The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity","volume":"4","author":"Bottcher","year":"2018","journal-title":"Trends Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical Role for CD103+\/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s00262-023-03421-7","article-title":"A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer","volume":"72","author":"Thomsen","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S406","DOI":"10.1016\/j.annonc.2024.08.511","article-title":"A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+\/CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG)","volume":"35","author":"Neyns","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"S719","DOI":"10.1016\/j.annonc.2024.08.1154","article-title":"1086P Intratumoral (IT) administration of autologous CD1c(BDCA-1)+\/CD141(BDCA-3)+myeloid dendritic cells (myDC) with the immunologic adjuvant AS01B plus ipilimumab (IPI) and IV nivolumab (NIVO) in patients with refractory advanced melanoma: A phase Ib clinical trial","volume":"35","author":"Vounckx","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.05.024","article-title":"Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy\u2019s initial experience with its first 100 patients","volume":"172","author":"Tselikas","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","article-title":"Talimogene laherparepvec: First in class oncolytic virotherapy","volume":"14","author":"Conry","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Schwarze, J.K., Awada, G., Cras, L., Tijtgat, J., Forsyth, R., Dufait, I., Tuyaerts, S., Van Riet, I., and Neyns, B. (2020). Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. Vaccines, 8.","DOI":"10.3390\/vaccines8040670"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e005141","DOI":"10.1136\/jitc-2022-005141","article-title":"Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: A phase I clinical trial","volume":"10","author":"Schwarze","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/CCO.0000000000000926","article-title":"Current \u201cstate of the art\u201d on dendritic cell-based cancer vaccines in melanoma","volume":"35","author":"Schwarze","year":"2023","journal-title":"Curr. Opin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Tijtgat, J., De Munck, J., Dufait, I., Schwarze, J.K., Van Riet, I., Franceschini, L., Breckpot, K., Aerts, J.L., Neyns, B., and Tuyaerts, S. (2021). Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.733506"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e008148","DOI":"10.1136\/jitc-2023-008148","article-title":"Intratumoral administration of the immunologic adjuvant AS01(B) in combination with autologous CD1c (BDCA-1)+\/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma","volume":"12","author":"Tijtgat","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.21037\/atm-21-491","article-title":"Current status of intralesional agents in treatment of malignant melanoma","volume":"9","author":"Zawit","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1200\/JCO-25-01346","article-title":"RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)","volume":"43","author":"Wong","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/5\/402\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:09:43Z","timestamp":1777547383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/5\/402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":89,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["vaccines14050402"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14050402","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}